Funding round brings in $33M for cholesterol drug developer

04/26/2013 | Xconomy

Esperion Therapeutics said it secured $33 million in a preferred stock funding round led by Longitude Capital and it will use the money to fund clinical trials. The Ann Arbor, Mich.-based firm is developing a cholesterol-lowering drug for patients who can't take statins. The drug, called ETC-1002, is in midstage development.

View Full Article in:

Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ